Recent Finacing
Recent Raise
ImmunoGenesis is a clinical-stage biotechnology company developing IMGS-001, a dual-specific PD-L1/PD-L2 cytotoxic antibody, advancing a first-in-human Phase 1a/1b trial targeting immune-resistant ovarian, colorectal, and triple-negative breast cancers.